Search

Your search keyword '"Tom Maishman"' showing total 42 results

Search Constraints

Start Over You searched for: Author "Tom Maishman" Remove constraint Author: "Tom Maishman" Topic business Remove constraint Topic: business
42 results on '"Tom Maishman"'

Search Results

1. Do surgical margins matter after mastectomy? A systematic review

2. Pathogenic Variants in CHEK2 Are Associated With an Adverse Prognosis in Symptomatic Early-Onset Breast Cancer

Catalog

Books, media, physical & digital resources

3. Effectiveness of nurse-led group CBT for hot flushes and night sweats in women with breast cancer: Results of the MENOS4 randomised controlled trial

4. Survival and disease characteristics of de novo versus recurrent metastatic breast cancer in a cohort of young patients

5. Immune reconstitution in children following chemotherapy for acute leukemia

6. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC):long-term results of a multicentre, randomised, controlled, phase 3 trial

7. Germline variation in ADAMTSL1 is associated with prognosis following breast cancer treatment in young women

8. Fractional Flow Reserve Derived from Computed Tomography Coronary Angiography in the Assessment and Management of Stable Chest Pain: Rationale and Design of the FORECAST Trial

9. Genome-wide association study of germline variants and breast cancer-specific mortality

11. P013: MENOS4 trial: Nurses can be trained to effectively deliver CBT for menopausal hot flushes in women with breast cancer to reduce hot flush bother and improve quality of life

12. Uva-ursi extract and ibuprofen as alternative treatments for uncomplicated urinary tract infection in women (ATAFUTI): a factorial randomized trial

13. The presentation, management and outcome of inflammatory breast cancer cases in the UK: Data from a multi-centre retrospective review

14. MENOS4 trial: a multicentre randomised controlled trial (RCT) of a breast care nurse delivered cognitive behavioural therapy (CBT) intervention to reduce the impact of hot flushes in women with breast cancer: Study Protocol

15. ACCEPT: A PHASE IB/II COMBINATION OF ACALABRUTINIB WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE AND PREDNISOLONE (R-CHOP) FOR PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)

16. Uva-Ursi Extract and Ibuprofen as Alternative Treatments of Adult Female Uncomplicated Urinary Tract Infection (Atafuti): A Double-Blind, Placebo-Controlled, Factorial Randomised Trial, and Open Pragmatic Trial

17. Obesity and the outcome of young breast cancer patients in the UK: the POSH study

18. Uva-ursi exract and ibuprofen as alternative treatments of adult female urinary tract infection (ATAFUTI): study protocol for a randomised controlled trial

19. Abstract P2-12-01: BRCA1 and BRCA2 in multifocal cancers: Results from the POSH study

20. Prospective Observational Study of Breast Cancer Treatment Outcomes for UK Women Aged 18–40 Years at Diagnosis: The POSH Study

21. Ethnicity and outcome of young breast cancer patients in the United Kingdom: the POSH study

22. Patterns of progression, treatment of progressive disease and post-progression survival in the New EPOC Study

23. Wilms’ tumour antigen 1 Immunity via DNA fusion gene vaccination in haematological malignancies by intramuscular injection followed by intramuscular electroporation: a Phase II non-randomised clinical trial (WIN)

24. Abstract S2-03: Does BRCA status affect outcome in young breast cancer patients? Results from the prospective study of outcomes in sporadic and hereditary breast cancer (POSH)

25. Abstract CT162: ACCEPT: A phase Ib/II combination of acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for patients with diffuse large B-cell lymphoma (DLBCL)

26. CONFIRM: A phase III randomized trial to evaluate the efficacy of nivolumab versus placebo in relapsed mesothelioma

27. Reply to ‘Comment on ‘BAG-1 as a biomarker in early breast cancer prognosis: a systematic review with meta-analyses’’

28. A review of the online prognositc model predict using the POSH cohort (women aged ≤40 years at breast cancer diagnosis)

29. CONFIRM: a phase III randomised trial to evaluate the efficacy of nivolumab versus placebo in relapsed mesothelioma

30. PUB035 CONFIRM: A Phase III Randomized Trial to Evaluate the Efficacy of Nivolumab versus Placebo in Relapsed Mesothelioma

31. Abstract PD6-02: Local recurrence in young women with invasive breast cancer; the prospective study of outcomes in sporadic and hereditary breast cancer (POSH)

34. A Prospective Randomised Trial of Targeted Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) Based upon Real-Time Gene Expression Profiling: The Remodl-B Study of the UK NCRI and SAKK Lymphoma Groups (ISRCTN51837425)

35. Real-Time Molecular Classification of Diffuse Large B-Cell Lymphoma (DLBCL) By Gene Expression Profiling (GEP): Successful Delivery of a Routine Service for Randomization of Patients Onto the Multicenter Remodl-B Trial (ISRCTN 51837425)

36. A Novel Phase Ii Trial of Ipilimumab, Carboplatin and Etoposide (Ice) for the First Line Treatment of Extensive Stage Small Cell Lung Cancer (Sclc)

37. Patterns of progression, treatment of progressive disease, and postprogression survival in the new EPOC study

38. Abstract P6-06-06: Family history and young breast cancer patients in the UK: The POSH study

39. ProCAID: a phase I clinical trial to combine the AKT inhibitor AZD5363 with docetaxel and prednisolone chemotherapy for metastatic castration resistant prostate cancer

40. Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy

41. A novel adaptive trial design: randomised evaluation of molecular guided therapy for diffuse large b-cell lymphoma with bortezomib (REMODL-B) with two interim analyses to explore safety and efficacy

42. Study protocol for a randomized controlled trial comparing the efficacy of a specialist and a generic parenting programme for the treatment of preschool ADHD